A Phase 3 interventional study of Pembrolizumab and Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]) in Urinary Bladder Cancer, Muscle-invasive, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 242 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing pembrolizumab in Urinary Bladder Neoplasms — 13 open to participants now, 20 under way, 5 of them phase 3. pembrolizumab · Urinary Bladder Neoplasms.
Among the 39 studies testing pembrolizumab in Urinary Bladder Neoplasms, this one is the 3rd largest by enrollment, is one of 4 that started in 2019, is one of 8 in phase 3, reaches primary completion later than 2 of the 19 other live ones, and was the 19th registered.
1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →13 of the 39 studies testing pembrolizumab in Urinary Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fox Chase Cancer Center · Sites in United States
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States, Canada, Korea, Republic of and 1 more country
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States, Australia, Canada and 9 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Canada
Ages 18+
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 26 · Phase 3 8
First in 2014; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 595 is above the median of 60 across 1,296 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 60 across the 39 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
17 studies in Urinary Bladder Neoplasms by Merck & Co., Inc: 5 open now, 9 under way, 5 of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 17 studies in Urinary Bladder Neoplasms by Merck & Co., Inc, this one is the 4th largest by enrollment, is one of 2 that started in 2019, is one of 7 in phase 3, and was the 7th registered.
Merck & Co., Inc’s Urinary Bladder Neoplasms studies by the year they started, since 2006.
7 of the studies testing pembrolizumab in Urinary Bladder Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04241185Phase 3Merck Sharp & Dohme LLCEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | 2027-01-31 |
| NCT04164082National Cancer Institute (NCI)Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer | 2026-12-09 |
| NCT05756569Emory UniversityEnfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology | 2026-12-16 |
| NCT04724018Dana-Farber Cancer InstituteSacituzumab Govitecan Plus EV in Metastatic UC | 2027-02-01 |
| NCT03504163Memorial Sloan Kettering Cancer CenterPembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)] | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 39 studies testing pembrolizumab in Urinary Bladder Neoplasms, from their registry updates:
Among Merck & Co., Inc’s 17 in Urinary Bladder Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC).
The primary hypothesis is that perioperative pembrolizumab plus radical cystectomy (RC) plus pelvic lymph node dissection (PLND) and perioperative enfortumab vedotin in combination with pembrolizumab plus RC+PLND will achieve superior event-free survival (EFS) compared with RC+PLND alone.
With Amendment 5, outcome measures for programmed cell death ligand 1 (PD-L1) combined positive score (CPS) were removed.
With Amendment 8, the primary outcome measure of pathologic complete response (pCR) rates was changed to a secondary outcome measure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ineligible for treatment with cisplatin, as defined by meeting at least one of the following criteria OR be eligible for treatment with cisplatin but decline treatment with cisplatin-based chemotherapy:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 3 preoperative cycles of pembrolizumab, followed by standard of care surgery, followed by 14 cycles of postoperative pembrolizumab. Each cycle is 21 days.
Drug: Pembrolizumab · Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Participants receive standard of care surgery alone.
Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Participants receive 3 preoperative cycles of enfortumab vedotin + pembrolizumab, followed by standard of care surgery, followed by 6 cycles of postoperative enfortumab vedotin + pembrolizumab, followed by 8 cycles of pembrolizumab alone. Each cycle is 21 days.
Drug: Enfortumab Vedotin
Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Also known as: KEYTRUDA®, MK-3475
Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
Enfortumab vedotin 1.25 mg/kg by intravenous (IV) infusion, given on Days 1 and 8 of each 21-day cycle.
Also known as: Padcev, ASG-22CE, ASG-22ME
Event-Free Survival (EFS) Between Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery and Arm B: Surgery Alone
EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes radical cystectomy + pelvic lymph node dissection (RC + PLND) surgery, failure to undergo RC + PLND surgery in participants with residual disease and any radiographic disease present (biopsy-proven muscle-invasive bladder cancer \[MIBC\] will be considered an event regardless of radiographic findings), gross residual disease left behind at the time of surgery, local or distant recurrence as assessed by imaging and/or biopsy, or death due to any cause.
Time frame: Up to approximately 53 months
EFS Between Arm A and Arm B
EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes RC surgery or failure to undergo RC surgery in participants with residual disease (biopsy-proven muscle-invasive bladder cancer \[MIBC\] will be considered an event regardless of radiographic findings), gross residual disease left behind at the time of surgery, local or distant recurrence as assessed by imaging and/or biopsy, or death due to any cause.
Time frame: Up to approximately 6.75 years
Overall Survival (OS) Between Arm C and Arm B
OS is defined as the time from randomization to death due to any cause.
Time frame: Up to approximately 7.6 years
OS Between Arm A and Arm B
OS is defined as the time from randomization to death due to any cause.
Time frame: Up to approximately 7.6 years
Pathologic Complete Response (pCR) Rate Between Arm C and Arm B
Pathologic complete response rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from RC and PLND, as assessed by blind independent central review (BICR).
Time frame: Up to approximately 53 monhts
pCR Rate Between Arm A and Arm B
Pathologic complete response rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from RC and PLND, as determined centrally.
Time frame: Up to approximately 5.7 years
Disease-Free Survival (DFS)
DFS is defined as the time from first post-surgery baseline scan until: * local or distant recurrence as assessed by imaging and/or biopsy * Death due to any cause
Time frame: Up to approximately 6.75 years
Pathologic Downstaging (pDS) Rate Between Arm A and Arm B
Pathologic downstaging rate is defined as the percentage of participants having pDS. pDS is defined as participants with a tumor classification of \<pT2 (includes pT0, pTis, pTa, pT1) and N0 in examined tissue from RC and PLND.
Time frame: Up to approximately 5.7 years
Pathologic Downstaging {pDS) Rate Between Arm C and Arm B
Pathologic downstaging (pDS) is defined as participants with a tumor classification of \<pT2. The pathologic stage \<pT2 includes pT0 (No residual primary tumor found in the tissue examined), pTis (carcinoma in situ; a flat, non-invasive cancer confined to the epithelial lining), pTa (Non-invasive papillary carcinoma limited to the urothelium) pT1 (tumor has invaded the connective tissue beneath the urothelium, but not the muscle layer) and N0 (No cancer found in the examined lymph nodes) in examined tissue from RC and PLND. The \<pT2 category represents a better outcome than participants with residual muscle-invasive disease (pT2 or higher) and/or any nodal involvement (N1/N2). The percentage of participants with pDS is presented.
Time frame: Up to approximately 53 months
Number of Participants Experiencing Adverse Events (AEs)
An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy can be determined.
Time frame: Up to approximately 7.6 years
Number of Participants Discontinuing Study Drug Due to Adverse Events (AEs)
An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy can be determined.
Time frame: Up to approximately 1 year
Number of Participants Experiencing Perioperative Complications
The number of participants who experience perioperative complications will be presented.
Time frame: Up to approximately 1 year
| Milestone | Arm A: Pembrolizumab + Surgery | Arm B: Surgery Alone | Arm C: Enfortumab Vedotin (EV) + Pembrolizumab + Surgery |
|---|---|---|---|
| Started | 166 | 259 | 170 |
| Treated | 166 | 236 | 170 |
| Completed | 0 | 0 | 0 |
| Not completed | 166 | 259 | 170 |
| Withdrew: Death | 74 | 108 | 37 |
| Withdrew: Withdrawal by subject | 3 | 8 | 3 |
| Withdrew: Ongoing | 89 | 143 | 130 |
EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes radical cystectomy + pelvic lymph node dissection (RC + PLND) surgery, failure to undergo RC + PLND surgery in participants with residual disease and any radiographic disease present (biopsy-proven muscle-invasive bladder cancer \[MIBC\] will be considered an event regardless of radiographic findings), gross residual disease left behind at the time of surgery, local or distant recurrence as assessed by imaging and/or biopsy, or death due to any cause.
| Months | Arm A: Pembrolizumab + Surgery | Arm B: Surgery Alone | Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery |
|---|---|---|---|
| Event-Free Survival (EFS) Between Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery and Arm B: Surgery Alone | — | 15.7 (10.3 to 20.5) | NA (37.3 to NA) |
EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes RC surgery or failure to undergo RC surgery in participants with residual disease (biopsy-proven muscle-invasive bladder cancer \[MIBC\] will be considered an event regardless of radiographic findings), gross residual disease left behind at the time of surgery, local or distant recurrence as assessed by imaging and/or biopsy, or death due to any cause.
Results for this outcome have not been posted.
OS is defined as the time from randomization to death due to any cause.
Results for this outcome have not been posted.
OS is defined as the time from randomization to death due to any cause.
Results for this outcome have not been posted.
Pathologic complete response rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from RC and PLND, as assessed by blind independent central review (BICR).
| Percentage of Participants | Arm A: Pembrolizumab + Surgery | Arm B: Surgery Alone | Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery |
|---|---|---|---|
| Pathologic Complete Response (pCR) Rate Between Arm C and Arm B | — | 8.6 (4.9 to 13.8) | 57.1 (49.3 to 64.6) |
Pathologic complete response rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from RC and PLND, as determined centrally.
Results for this outcome have not been posted.
DFS is defined as the time from first post-surgery baseline scan until: * local or distant recurrence as assessed by imaging and/or biopsy * Death due to any cause
Results for this outcome have not been posted.
Pathologic downstaging rate is defined as the percentage of participants having pDS. pDS is defined as participants with a tumor classification of \<pT2 (includes pT0, pTis, pTa, pT1) and N0 in examined tissue from RC and PLND.
Results for this outcome have not been posted.
Pathologic downstaging (pDS) is defined as participants with a tumor classification of \<pT2. The pathologic stage \<pT2 includes pT0 (No residual primary tumor found in the tissue examined), pTis (carcinoma in situ; a flat, non-invasive cancer confined to the epithelial lining), pTa (Non-invasive papillary carcinoma limited to the urothelium) pT1 (tumor has invaded the connective tissue beneath the urothelium, but not the muscle layer) and N0 (No cancer found in the examined lymph nodes) in examined tissue from RC and PLND. The \<pT2 category represents a better outcome than participants with residual muscle-invasive disease (pT2 or higher) and/or any nodal involvement (N1/N2). The percentage of participants with pDS is presented.
| Percentage of Participants | Arm A: Pembrolizumab + Surgery | Arm B: Surgery Alone | Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery |
|---|---|---|---|
| Pathologic Downstaging {pDS) Rate Between Arm C and Arm B | — | 12.6 (8.1 to 18.5) | 65.9 (58.2 to 73.0) |
An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy can be determined.
Results for this outcome have not been posted.
An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy can be determined.
Results for this outcome have not been posted.
The number of participants who experience perioperative complications will be presented.
Results for this outcome have not been posted.
Collected over Up to approximately 69 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Pembrolizumab + Surgery | 76/166 (45.8%) | 107/163 (65.6%) | 143/163 (87.7%) |
| Arm B: Surgery Alone | 111/259 (42.9%) | 94/242 (38.8%) | 94/242 (38.8%) |
| Arm C: EV + Pembrolizumab + Surgery | 38/170 (22.4%) | 97/167 (58.1%) | 163/167 (97.6%) |
| Event | Arm A: Pembrolizumab + Surgery | Arm B: Surgery Alone | Arm C: EV + Pembrolizumab + Surgery |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 15/163 | 17/242 | 17/167 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 13/163 | 11/242 | 3/167 |
| Acute kidney injuryRenal and urinary disorders | 5/163 | 3/242 | 8/167 |
| PyelonephritisInfections and infestations | 7/163 | 2/242 | 6/167 |
| SepsisInfections and infestations | 7/163 | 7/242 | 5/167 |
| UrosepsisInfections and infestations | 3/163 | 8/242 | 7/167 |
| PneumoniaInfections and infestations | 5/163 | 2/242 | 5/167 |
| HydronephrosisRenal and urinary disorders | 5/163 | 3/242 | 1/167 |
| Intestinal obstructionGastrointestinal disorders | 4/163 | 2/242 | 4/167 |
| Postoperative wound infectionInfections and infestations | 4/163 | 1/242 | 1/167 |
| Event | Arm A: Pembrolizumab + Surgery | Arm B: Surgery Alone | Arm C: EV + Pembrolizumab + Surgery |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 28/163 | 1/242 | 78/167 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/163 | 0/242 | 58/167 |
| DiarrhoeaGastrointestinal disorders | 23/163 | 7/242 | 54/167 |
| FatigueGeneral disorders | 26/163 | 12/242 | 54/167 |
| AnaemiaBlood and lymphatic system disorders | 49/163 | 27/242 | 51/167 |
| Decreased appetiteMetabolism and nutrition disorders | 23/163 | 9/242 | 47/167 |
| DysgeusiaNervous system disorders | 5/163 | 0/242 | 47/167 |
| ConstipationGastrointestinal disorders | 23/163 | 18/242 | 44/167 |
| NauseaGastrointestinal disorders | 21/163 | 16/242 | 43/167 |
| RashSkin and subcutaneous tissue disorders | 16/163 | 2/242 | 41/167 |
| Age, Continuous(Years) | Arm A: Pembrolizumab + Surgery | Arm B: Surgery Alone | Arm C: Enfortumab Vedotin (EV) + Pembrolizumab + Surgery | Total |
|---|---|---|---|---|
| Mean | 71.8 ± 7.9 | 71.9 ± 7.7 | 72.1 ± 7.9 | 71.9 ± 7.8 |
| Sex: Female, Male(Participants) | Arm A: Pembrolizumab + Surgery | Arm B: Surgery Alone | Arm C: Enfortumab Vedotin (EV) + Pembrolizumab + Surgery | Total |
|---|---|---|---|---|
| Female | 36 | 66 | 33 | 135 |
| Male | 130 | 193 | 137 | 460 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Pembrolizumab + Surgery | Arm B: Surgery Alone | Arm C: Enfortumab Vedotin (EV) + Pembrolizumab + Surgery | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 15 | 8 | 26 |
| Not Hispanic or Latino | 155 | 231 | 160 | 546 |
| Unknown or Not Reported | 8 | 13 | 2 | 23 |
| Race (NIH/OMB)(Participants) | Arm A: Pembrolizumab + Surgery | Arm B: Surgery Alone | Arm C: Enfortumab Vedotin (EV) + Pembrolizumab + Surgery | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 16 | 38 | 31 | 85 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 2 | 7 |
| White | 148 | 205 | 132 | 485 |
| More than one race | 0 | 7 | 4 | 11 |
| Unknown or Not Reported | 1 | 4 | 1 | 6 |
| Cisplatin Status(Participants) | Arm A: Pembrolizumab + Surgery | Arm B: Surgery Alone | Arm C: Enfortumab Vedotin (EV) + Pembrolizumab + Surgery | Total |
|---|---|---|---|---|
| Cisplatin-Ineligible | 163 | 223 | 142 | 528 |
| Cisplatin-Eligible but Declined | 3 | 36 | 28 | 67 |
| Tumor Clinical Stage(Participants) | Arm A: Pembrolizumab + Surgery | Arm B: Surgery Alone | Arm C: Enfortumab Vedotin (EV) + Pembrolizumab + Surgery | Total |
|---|---|---|---|---|
| T2N0 | 12 | 40 | 30 | 82 |
| T3/T4aN0 | 150 | 209 | 133 | 492 |
| T1-4aN1 | 4 | 10 | 7 | 21 |
| Geographic Region(Participants) | Arm A: Pembrolizumab + Surgery | Arm B: Surgery Alone | Arm C: Enfortumab Vedotin (EV) + Pembrolizumab + Surgery | Total |
|---|---|---|---|---|
| United States (US) | 19 | 33 | 21 | 73 |
| European Union (EU) | 73 | 110 | 78 | 261 |
| Most of World (MOW) | 74 | 116 | 71 | 261 |
Showing the first 100 of 242 sites across 28 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jul 2019 to primary completion in Jun 2025, 70 months.
Results were first posted in Jun 2026, 1 year after primary completion.
Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's 70 months is above that.
Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pembrolizumab · Enfortumab vedotin